Consensus Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Delayed TEL AVIV STOCK EXCHANGE 08:49:47 2024-05-12 am EDT 5-day change 1st Jan Change
6,030 ILa +2.73% Intraday chart for Teva Pharmaceutical Industries Limited +15.81% +58.06%

Evolution of the average Target Price on Teva Pharmaceutical Industries Limited

Price target over the last 5 years

History of analyst recommendation changes

b8e1.I5FYLcYXU2T3e9f7Yop6U2A4n5kxj_miCnFEnby-6Ec.V6I6V_FRZFyeKrCUV-QjCwtfrN99_snTRQcFwszJhw971ih-lmEAB4RLng~278b0c2a43a539aa271810a37bda64fb
Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating MT
JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11 MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12 MT
Goldman Sachs Adjusts Price Target on Teva Pharmaceutical Industries to $11 From $10, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $17 From $15, Maintains Overweight Rating MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $15 From $14, Maintains Overweight Rating MT
Teva: share price up, broker in support CF
TEVA : Jefferies raises its recommendation CF
Jefferies Upgrades Teva Pharmaceutical Industries to Buy From Hold, Raises Price Target to $14 From $10 MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Buy Rating MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Raises Price Target to $12 From $8 MT
HSBC Initiates Teva Pharmaceutical Industries at Buy Rating With $13 Price Target MT
UBS Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $11 MT
UBS Upgrades Teva Pharmaceutical Industries to Neutral From Sell, Raises Price Target to $8 From $7 MT
Evercore ISI Upgrades Teva Pharmaceutical Industries to Outperform From In-Line MT
Barclays Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Overweight Rating MT
Jefferies Downgrades Teva Pharmaceutical Industries to Hold From Buy, Adjusts Price Target to $12 From $10 MT
UBS Downgrades Teva Pharmaceutical Industries to Sell From Neutral, Adjusts Price Target to $7 From $10 MT
Jefferies Assumes Teva Pharmaceutical Industries at Buy with $10 Price Target MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $11 From $13, Maintains Buy Rating MT
BofA Securities Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $10 MT
ANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone... Our Logo
BofA Securities Upgrades Teva Pharmaceutical Industries to Neutral From Underperform; Price Target is $9 MT
Piper Sandler Downgrades Teva Pharmaceutical Industries to Underweight From Neutral, Adjusts Price Target to $7 From $11 MT
Barclays Lifts Teva Pharmaceutical Industries to Overweight From Equalweight, Price Target to $13 From $11 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
16.88 USD
Average target price
17.34 USD
Spread / Average Target
+2.70%
High Price Target
20 USD
Spread / Highest target
+18.48%
Low Price Target
14.5 USD
Spread / Lowest Target
-14.10%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Teva Pharmaceutical Industries Limited

Piper Sandler
JPMorgan Chase
Goldman Sachs
Barclays
Jefferies & Co.
BofA Securities
HSBC
UBS
Evercore ISI
Bernstein
Argus
Raymond James
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. TEVA Stock
  5. Consensus Teva Pharmaceutical Industries Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW